Author:
Fujiwara Yasuhiro,Mukai Hirofumi,Saeki Toshiaki,Ro Jungsil,Lin Yung-Chang,Nagai Shigenori E.,Lee Keun Seok,Watanabe Junichiro,Ohtani Shoichiro,Kim Sung Bae,Kuroi Katsumasa,Tsugawa Koichiro,Tokuda Yutaka,Iwata Hiroji,Park Yeon Hee,Yang Youngsen,Nambu Yoshihiro
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, 349–386 (2015).
2. Hamaguchi, T. et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92, 1240–1246 (2005).
3. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986).
4. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 65, 271–284 (2000).
5. Mukai, H. et al. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Invest. New Drugs 34, 750–759 (2016).
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献